OPTIMIZERX CORP

Optimizerx’s sharp rally—driven by Royce & Associates’ 7% stake—raises questions about thin liquidity and an unproven prescription‑saving model. Understand the risks before buying.

Optimizerx shares climb 18% year‑to‑date; see OPRX 2.17% rise, 52‑week high, and peer performance plus RxSight Q3 results coming Nov 3.